Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Healthy Vietnamese Women According to a 0, 1, 6 Month Schedule

NCT00572000 ↗

Unknown 222 enrolled National Institute for Control of Vaccine and Biologicals

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to assess the occurrence of serious adverse events (SAEs) as well as evaluate the occurrence of solicited local and solicited general symptoms and the occurrence of medically significant conditions reported throughout the study period.

Timeline

Start: 2007-11
Primary completion: —
Completion: 2008-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HPV 16/18 VLP AS04	Vaccine	0.5 ml	Intramuscular

Indications

No indication recorded.